Home / CABA : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does CABA make money? Does CABA have pricing power? What's the Earnings Whisper? Will CABA profit more as the business scales? What is CABA's management track record? Is CABA's current price justified?

Cabaletta Bio, Inc.

$2.91 +$0.70 (+31.67%)

NASDAQ · 14 Sep 2026 20:00 UTC

Previous Close

$2.73

Day Range

$2.71$3.04

Year Range

$1.91$4.23

Market Cap

474.49M

AVG Volume

4.71M

Trailing/Forward PE

-1.84/-

PEG ratio

0.15

Dividend Yield

Next Earnings Date

2026-11-09

Primary Exchange

NASDAQ

Net Income (USD) · TTM

CABA Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-181.32M
26 Q1	-175.43M
25 Q4	-167.86M
25 Q3	-158.52M
25 Q2	-144.29M
25 Q1	-126.76M
24 Q4	-115.86M
24 Q3	-104.16M
24 Q2	-89.98M
24 Q1	-76.87M

Operating Income (USD) · TTM

CABA Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-185.52M
26 Q1	-179.4M
25 Q4	-172.24M
25 Q3	-163.41M
25 Q2	-149.87M
25 Q1	-134.25M
24 Q4	-125.14M
24 Q3	-114.5M
24 Q2	-100.12M
24 Q1	-85.73M

EBITDA (USD) · TTM

CABA EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-176.92M
26 Q1	-171.58M
25 Q4	-164.21M
25 Q3	-146.48M
25 Q2	-132.75M
25 Q1	-115.84M
24 Q4	-105.33M
24 Q3	-102.58M
24 Q2	-88.47M
24 Q1	-75.41M

Cash Flows (USD) · TTM

CABA Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-154.21M
26 Q1	-143.28M
25 Q4	-132.31M
25 Q3	-120.26M
25 Q2	-106.25M
25 Q1	-97.22M
24 Q4	-90.43M
24 Q3	-83.57M
24 Q2	-75.66M
24 Q1	-66.05M

EPS (USD) · TTM

CABA EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-1.58
26 Q1	-1.97
25 Q4	-2.31
25 Q3	-2.55
25 Q2	-2.73
25 Q1	-2.56
24 Q4	-2.34
24 Q3	-2.16
24 Q2	-1.91
24 Q1	-1.72

Expenses (USD) · TTM

CABA Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	185.8M
26 Q1	179.84M
25 Q4	173.47M
25 Q3	164.81M
25 Q2	151.45M
25 Q1	136.43M
24 Q4	127.35M
24 Q3	116.52M
24 Q2	101.96M
24 Q1	86.85M

Shares Outstanding (USD) · TTM

CABA Shares Outstanding (USD) · TTM by quarter
Period	Shares Outstanding (USD) · TTM
26 Q2	-20.83M
26 Q1	-21.03M
25 Q4	-20.94M
25 Q3	-22.09M
25 Q2	-21.53M
25 Q1	-20.84M
24 Q4	-19.46M
24 Q3	-17.11M
24 Q2	-14.86M
24 Q1	-12.65M

Employee Count

CABA Employee Count by quarter
Period	Employee Count
2025	154
2024	161
2023	101
2022	58
2021	53
2020	33
2019	22

Free Cash Flow Yield

CABA Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-35.06%
Sep 26	-37.37%
Sep 26	-29.4%
Aug 26	-32.7%
Aug 26	-32.59%
Aug 26	-37.1%
Aug 26	-45.84%
Jul 26	-47.72%
Jul 26	-47.55%
Jul 26	-45.2%
Jul 26	-42.92%
Jul 26	-40.09%
Jun 26	-42.07%
Jun 26	-45.04%
Jun 26	-42.49%
Jun 26	-39.35%
May 26	-33.84%
May 26	-35.04%
May 26	-38.64%
May 26	-33.35%
May 26	-44.01%
Apr 26	-43.86%
Apr 26	-37.61%
Apr 26	-41.34%
Apr 26	-43.71%
Mar 26	-48.28%
Mar 26	-40%
Mar 26	-38.43%
Mar 26	-37.1%
Feb 26	-35.42%
Feb 26	-40.41%
Feb 26	-42%
Feb 26	-46.85%
Jan 26	-45.76%
Jan 26	-36.98%
Jan 26	-53.45%
Jan 26	-56%
Jan 26	-53.21%
Dec 25	-53.7%
Dec 25	-49.2%
Dec 25	-49.83%
Dec 25	-46.12%
Nov 25	-45.76%
Nov 25	-56.54%
Nov 25	-50.91%
Nov 25	-67.34%
Oct 25	-47.56%
Oct 25	-69.52%
Oct 25	-60.25%
Oct 25	-74.01%
Oct 25	-70.37%
Sep 25	-72.76%
Sep 25	-78.41%
Sep 25	-93.32%
Sep 25	-101.01%
Aug 25	-118.42%
Aug 25	-105.99%
Aug 25	-100.41%
Aug 25	-126.26%
Aug 25	-136.47%
Jul 25	-118.39%
Jul 25	-117.68%
Jul 25	-112.94%
Jul 25	-120.56%
Jun 25	-125.17%
Jun 25	-109.79%
Jun 25	-98.75%
Jun 25	-79.24%
May 25	-105.09%
May 25	-112.3%
May 25	-96.81%
May 25	-151.59%
May 25	-134.62%
Apr 25	-142.04%
Apr 25	-163.99%
Apr 25	-146.66%
Apr 25	-162.51%
Mar 25	-110.17%
Mar 25	-98.14%
Mar 25	-93.83%
Mar 25	-92.3%
Feb 25	-94.34%
Feb 25	-82.89%
Feb 25	-63.01%
Feb 25	-64.44%
Jan 25	-71.45%
Jan 25	-68.31%
Jan 25	-62.32%
Jan 25	-82.1%
Jan 25	-71.15%
Dec 24	-74.57%
Dec 24	-71.75%
Dec 24	-60.55%
Dec 24	-51.75%
Nov 24	-44.7%
Nov 24	-91.32%
Nov 24	-56.36%
Nov 24	-34.43%
Nov 24	-41.67%
Oct 24	-39.54%

Price to Book

CABA Price to Book by quarter
Period	Price to Book
Sep 26	2.09
Sep 26	1.96
Sep 26	2.49
Aug 26	2.24
Aug 26	2.25
Aug 26	1.97
Aug 26	3.03
Jul 26	2.91
Jul 26	2.92
Jul 26	3.07
Jul 26	3.23
Jul 26	3.46
Jun 26	3.3
Jun 26	3.08
Jun 26	3.26
Jun 26	3.52
May 26	4.1
May 26	3.96
May 26	3.59
May 26	3.54
May 26	2.68
Apr 26	2.69
Apr 26	3.14
Apr 26	2.86
Apr 26	2.7
Mar 26	2.45
Mar 26	2.16
Mar 26	2.24
Mar 26	2.32
Feb 26	2.43
Feb 26	2.13
Feb 26	2.05
Feb 26	1.84
Jan 26	1.88
Jan 26	2.33
Jan 26	1.61
Jan 26	1.54
Jan 26	1.62
Dec 25	1.61
Dec 25	1.75
Dec 25	1.73
Dec 25	1.87
Nov 25	1.88
Nov 25	1.53
Nov 25	1.69
Nov 25	0.88
Oct 25	1.25
Oct 25	0.86
Oct 25	0.99
Oct 25	0.8
Oct 25	0.85
Sep 25	0.82
Sep 25	0.76
Sep 25	0.64
Sep 25	0.59
Aug 25	0.5
Aug 25	0.56
Aug 25	0.59
Aug 25	0.47
Aug 25	0.59
Jul 25	0.68
Jul 25	0.68
Jul 25	0.71
Jul 25	0.66
Jun 25	0.64
Jun 25	0.73
Jun 25	0.81
Jun 25	1.01
May 25	0.76
May 25	0.71
May 25	0.83
May 25	0.39
May 25	0.44
Apr 25	0.42
Apr 25	0.36
Apr 25	0.4
Apr 25	0.37
Mar 25	0.44
Mar 25	0.49
Mar 25	0.51
Mar 25	0.52
Feb 25	0.51
Feb 25	0.58
Feb 25	0.76
Feb 25	0.74
Jan 25	0.67
Jan 25	0.7
Jan 25	0.77
Jan 25	0.58
Jan 25	0.67
Dec 24	0.64
Dec 24	0.67
Dec 24	0.79
Dec 24	0.93
Nov 24	1.07
Nov 24	0.53
Nov 24	0.85
Nov 24	1.1
Nov 24	0.91
Oct 24	0.96

No video analysis for this stock yet. Request one from our team.

News: CABA

seekingalpha.com · 14 Sep 2026

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

globenewswire.com · 1 Sep 2026

Cabaletta Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.

globenewswire.com · 13 Aug 2026

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

seekingalpha.com · 26 Jun 2026

Cabaletta Bio: The Market Sold The EULAR News, I'm Buying

Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.